Iterum Therapeutics Plc (ITRM) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
H.C. Wainwright Upgrades Iterum Therapeutics (ITRM) to Buy
March 15, 2021 6:21 AM EDTH.C. Wainwright analyst Ed Arce upgraded Iterum Therapeutics (NASDAQ: ITRM) from Neutral to Buy with a price target of $2.50.
The analyst comments "Recent financings provide substantial runway, allowing investor focus to turn to potential FDA approval and launch. We downgraded ITRM last June on an unclear regulatory path forward for sulopenem (it had missed the primary endpoint on two of three Phase 3 trials) and a short cash runway without an ability to commercialize the drug (or a partner), even... More
